Terms: = Lung cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1
75146 results:
1. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract] [Full Text] [Related]
2. Strategies to address recruitment to a randomised trial of surgical and non-surgical treatment for cancer: results from a complex recruitment intervention within the Mesothelioma and Radical Surgery 2 (MARS 2) study.
Mills N; Farrar N; Warnes B; Ashton KE; Harris R; Rogers CA; Lim E; Elliott D
BMJ Open; 2024 May; 14(5):e079108. PubMed ID: 38760029
[TBL] [Abstract] [Full Text] [Related]
3. Association of Remote Patient-Reported Outcomes and Step Counts With Hospitalization or Death Among Patients With Advanced cancer Undergoing Chemotherapy: Secondary Analysis of the PROStep Randomized Trial.
Manz CR; Schriver E; Ferrell WJ; Williamson J; Wakim J; Khan N; Kopinsky M; Balachandran M; Chen J; Patel MS; Takvorian SU; Shulman LN; Bekelman JE; Barnett IJ; Parikh RB
J Med Internet Res; 2024 May; 26():e51059. PubMed ID: 38758583
[TBL] [Abstract] [Full Text] [Related]
4. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract] [Full Text] [Related]
5. Exploring Guolin Qigong (Mind-Body Exercise) for Improving cancer Related Fatigue in cancer Survivors: A Mixed Method Randomized Controlled Trial Protocol.
Low SLK; Ho GF; Liu B; Koh ES; Fei Y; Teo CS; Zhu X
Integr Cancer Ther; 2024; 23():15347354241252698. PubMed ID: 38757745
[TBL] [Abstract] [Full Text] [Related]
6. Clinic information, pathological, and imaging characteristics in 2 058 surgical patients with lung cancer from a single center.
Long B; Xiong Z; Liu S; Cheng Y; Li M; Liao W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):247-255. PubMed ID: 38755720
[TBL] [Abstract] [Full Text] [Related]
7. Scoping review of exposure questionnaires and surveys in interstitial lung disease.
Barnes H; Elmrayed S; Barber CM; Feary J; Lee CT; Gandhi S; Peters CE; Salisbury ML; Johannson KA
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754906
[TBL] [Abstract] [Full Text] [Related]
8. Non-Small Cell lung cancer, Version 4.2024.
Riely GJ; Wood DE; Ettinger DS; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; DeCamp M; Desai AP; Dilling TJ; Dowell J; Durm GA; Gettinger S; Grotz TE; Gubens MA; Juloori A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Mullikin TC; Ng T; Owen D; Owen DH; Patel SP; Patil T; Polanco PM; Riess J; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory KM; Hang L
J Natl Compr Canc Netw; 2024 May; 22(4):249-274. PubMed ID: 38754467
[TBL] [Abstract] [Full Text] [Related]
9. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
10. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
[TBL] [Abstract] [Full Text] [Related]
11. Deep-Learning Model Prediction of Radiation Pneumonitis Using Pretreatment Chest Computed Tomography and Clinical Factors.
Lee JH; Kang MK; Park J; Lee SJ; Kim JC; Park SH
Technol Cancer Res Treat; 2024; 23():15330338241254060. PubMed ID: 38752262
[No Abstract] [Full Text] [Related]
12. Evaluation of sex inequity in lung-cancer-specific survival.
Lærum D; Strand TE; Brustugun OT; Gallefoss F; Falk R; Durheim MT; Fjellbirkeland L
Acta Oncol; 2024 May; 63():343-350. PubMed ID: 38751329
[TBL] [Abstract] [Full Text] [Related]
13. The prevalence and mortality risks of PRISm and COPD in the United States from NHANES 2007-2012.
Cadham CJ; Oh H; Han MK; Mannino D; Cook S; Meza R; Levy DT; Sánchez-Romero LM
Respir Res; 2024 May; 25(1):208. PubMed ID: 38750492
[TBL] [Abstract] [Full Text] [Related]
14. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
[TBL] [Abstract] [Full Text] [Related]
15. Understanding the interplay of colorectal cancer awareness and attitudes among Palestinians: a national cross-sectional study.
Elshami M; Dwikat MF; Al-Slaibi I; Alser M; Albandak ME; Ayyad M; Naji SA; Mohamad BM; Isleem WS; Shurrab A; Yaghi B; Qabaja YA; Hamdan FK; Sweity RR; Jneed RT; Assaf KA; Hmaid MM; Awwad II; Alhabil BK; Alarda MN; Alsattari AS; Aboyousef MS; Aljbour OA; AlSharif R; Giacaman CT; Alnaga AY; Nemer RMA; Almadhoun NM; Skaik SM; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Cancer; 2024 May; 24(1):590. PubMed ID: 38750448
[TBL] [Abstract] [Full Text] [Related]
16. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract] [Full Text] [Related]
17. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
18. Perioperative Nivolumab in Resectable lung cancer.
Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
[TBL] [Abstract] [Full Text] [Related]
19. Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types.
Kang J; Lee JH; Cha H; An J; Kwon J; Lee S; Kim S; Baykan MY; Kim SY; An D; Kwon AY; An HJ; Lee SH; Choi JK; Park JE
Nat Commun; 2024 May; 15(1):4067. PubMed ID: 38744958
[TBL] [Abstract] [Full Text] [Related]
20. Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer.
Zhang T; Chu L; Tan W; Ye C; Dong H
Clin Respir J; 2024 May; 18(5):e13774. PubMed ID: 38742362
[TBL] [Abstract] [Full Text] [Related]
[Next]
